Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Assessment of SARS-CoV-2 specific CD4(+) and CD8 (+) T cell responses using MHC class I and II tetramers

Yuri Poluektov a, Marybeth George b, Pirouz Daftarian b, Marc C. Delcommenne a,⇑

a MBL International, 15A Constitution Way, Woburn, MA 01801, United States
b JSR Life Sciences, 1280 N Mathilda Ave, Sunnyvale, CA 94089, United States

Abstract

The success of SARS-CoV-2 (CoV-2) vaccines is measured by their ability to mount immune memory responses that are long-lasting. To achieve this goal, it is important to identify surrogates of immune protection, namely, CoV-2 MHC Class I and II immunodominant pieces/epitopes and methodologies to measure them. Here, we present results of flow cytometry-based MHC Class I and II QuickSwitch™ platforms for assessing SARS-CoV-2 peptide binding affinities to various human alleles as well as the H-2 Kb mouse allele. Multiple SARS-CoV-2 potential MHC binders were screened and validated by QuickSwitch testing. The screen included 31 MHC Class I and 19 MHC Class II peptides predicted to be good binders by the IEDB web resource provided by NIAID. While several predicted peptides with acceptable theoretical Kd showed poor MHC occupancies, fourteen MHC class II and three MHC class I peptides showed promiscuity in that they bind to multiple MHC molecule types. In addition to providing important data towards the study of the SARS-CoV-2 virus and its presented antigenic epitopes, the peptides identified in this study can be used in the QuickSwitch platform to generate MHC tetramers. With those tetramers, scientists can assess CD4 + and CD8 + immune responses to these different MHC/peptide complexes.

1. Introduction

While various antiviral drugs or passive antibody therapies are attractive approaches as a bridge to a vaccine, the consensus is that immunization and mounting durable immune memory against the SARS-CoV-2 is an unavoidable task facing today’s scientific community [1]. The basic research to uncover the exact mechanisms of how the SARS-CoV-2 virus is perceived and countered by the human immune system have been more difficult. In the effort to fight this outbreak, a greater understanding of how the viral proteins and their processed peptides stimulate the immune responses mediated by CD8 + and CD4 + T lymphocytes is needed. While some tremendous research has been undertaken with an impressive swiftness to determine the specific viral peptides that lead to an effective T cell response, many of the identified SARS-CoV-2-reactive T-cells were also found in healthy donors [2,3]. This, in turn, raises even more questions as to the nature of the viral peptides needed to mount an effective immune response. In addition, this creates a vital need for a fast and effective way to generate various MHC tetramers needed to detect the numerous specific T cells that will be researched while trying to determine the best possible viral peptides that would stimulate the most effective T cells.

The ability of a peptide to stimulate the immune system stems from such properties as the availability of the right T cell receptor, antigen processability by the antigen processing system that could generate the peptide in question, and the peptide's ability to occupy the cleft of the MHC molecule [4,5]. It has been observed that more than 80% of MHC class I-bound peptides derived from a virus can be immunogenic [6]. At least in the case of viral peptides, peptides that that have a high binding affinity to MHC Class I molecules tend to also be immunogenic [7,8]. To this end, we utilized the QuickSwitch antigen presentation platform (MBL International) based on the peptide exchange principle [9]. This platform allows users to quantitate the relative ability of MHC molecules to bind a particular peptide, as well as to generate an MHC tetramer that can be used to stain T cells in flow cytometry experiments. The system relies on an irrelevant and weak binding peptide, called exiting peptide, which comes pre-loaded into the recombinant MHC molecule that you wish to study. When the QuickSwitch MHC molecule is presented with a competing

Abbreviations: PEF, Peptide Exchange Factor.
⇑ Corresponding author at: MBL International, 15A Constitution Way, Woburn, MA 01801, United States.
E-mail address: marc.delcommenne@mblintl.com (M.C. Delcommenne).

https://doi.org/10.1016/j.vaccine.2021.03.008
0264-410X/© 2021 Elsevier Ltd. All rights reserved.
peptide, the exiting peptide will be replaced proportionally to the MHC binding affinity of the competing peptide. In addition, a FITC-labeled antibody against the exiting peptide comes included in every kit so that the extent of the peptide exchange can be measured using a simple flow cytometry procedure with magnetic beads specific for the MHC molecule being tested. In this short study we would like to report how the QuickSwitch platform can be used to screen SARS-CoV-2 peptides for their ability to bind various MHC molecules. This short collection of findings helps avoid unnecessary experiments with SARS-CoV-2 peptides that cannot be presented by MHC molecules and allows for the construction of working MHC tetramers that can be used for productive CD8 + and CD4 + cell staining.

2. Materials and methods

The peptide binding tests to determine the peptide’s affinity for a specific MHC haplotype were performed on a 50 μg/mL (MHC concentration) solution of tetramers for the MHC Class I molecules or a 100 μg/mL solution of recombinant MHC biotinylated molecules for MHC Class II. While it is possible to get valid peptide exchange results by decreasing the Tetramer or monomer concentration even further, it is not recommended, as some MHC haplotypes are much more sensitive to dilution than others generating different results depending on the MHC concentration.

2.1. MHC Class I peptide exchange procedures

All Class I exchanges were performed according to the standard procedures designed for each QuickSwitch kit. Briefly, 50 μL of the tetramer at 50 μg/mL was mixed with 1 μL of peptide diluted to 1 mM in H2O and 1 μL of the proprietary Peptide Exchange Factor (PEF) corresponding to the particular MHC haplotype. HLA-A*02:01, HLA-A*24:02 and H-2 Kb received 1 μL of Peptide Exchange Factor #1 (PEF#1) (MBL: KXT-T07050). HLA-A*11:01 received 1 μL of Peptide Exchange Factor #2 (PEF#2) (MBL: KXT-T07051). And HLA-A*03:01 received 1 μL of Peptide Exchange Factor #3 (PEF#3) (MBL: KXT-T07052). The resulting solution, containing 50 μg/mL Tetramer, 20 μM peptide to be loaded into the MHC molecule and 1 μL of the peptide exchange factor was incubated in a conical-bottom 96 well PCR plate for 4 h at room temperature (∼22 °C). A more detailed description of the standard procedures can be found in the MBL International QuickSwitch™ Quant Tetramer Kit Data Sheet.

2.2. Capture assay to determine the binding affinity of a peptide for a particular MHC haplotype

Following the incubation, the percentage of MHC molecules that were loaded with the test peptide from the total MHC molecules containing the exiting peptide was determined by performing a capture assay described in the MBL International QuickSwitch™ Quant Tetramer Kit Data Sheet. Briefly, 20 μL of magnetic beads linked with an anti HLA-ABC antibody (MBL: KXT-T07100 provided in the kit) were added into sample wells of a V-bottom 96-well microtiter plate with 5 μL of the Tetramer peptide exchange solution (from the 52 μL total volume). The microplate was shaken for 45 min at 550 RPM, protected from light with a sheet of aluminum foil. Following the shaking incubation, all sample wells were washed with 150 μL of assay buffer (MBL: KXT-T07000 provided in the kit, must be diluted 1:10 before use), utilizing the magnetic qualities of the beads by letting them sediment while the plate is immobilized on a magnetic tray. The excess buffer was decanted out of the plate by flicking while it was being held tight to the magnetic tray. After the rinse each well received 25 μL of exiting peptide antibody-FITC solution (MBL: KXT-T07200 provided in the kit, must be diluted 1:25 before use). The microplate containing the magnetic beads with the bound MHC tetramers and the exiting peptide antibody was shaken again for 45 min at 550 RPM, protected from light with a sheet of aluminum foil. The samples were washed with another 150 μL volume of assay buffer and resuspended in 150 μL of assay buffer before the fluorescent signals of each sample were recorded on a flow cytometer.

2.3. MHC Class II peptide exchange procedures

For MHC Class II peptide exchange we followed the parameters of QuickSwitch Quant HLA-DRB1*01:01, HLA-DRB1*04:01 and HLA-DRB1*15:01 tetramer kits. 25 μL of a 100 μg/mL biotinylated MHC Class II QuickSwitch molecule was mixed with 3 μL of peptide stock diluted to 10 mM in 100% DMSO and 2 μL of Emulsifier #1 (MBL: KXT-T07070 provided in the kit). The resulting solution, containing 100 μg/mL MHC Class II molecule, 1 mM peptide (or tenfold dilutions) to be loaded into the MHC Class II molecule and 2 μL of the proprietary Emulsifier #1 was incubated in a conical-bottom 96 well PCR plate overnight (>10 h) at 37 °C.

The capture assay was performed with nearly identical procedures to the ones used for the MHC Class I tetramers. 25 μL of streptavidin conjugated magnetic beads (MBL: KXT-T07101 provided in the kit) were used to capture 1 μL of the 30 μM MHC Class II peptide exchange reaction. The MHC molecules were captured by the magnetic beads after shaking the V-bottom 96-well microtiter plate for 45 min at 550 RPM. Following a 150 μL wash with peptide exchange assay buffer #2 (MBL: KXT-T07001 provided in the kit, must be diluted 1:10 before use) the exchanged MHC Class II molecules were stained with 25 μL of exiting peptide antibody-FITC (MBL: KXT-T07201 provided in the kit). The antibody was allowed to stain the captured MHC Class II molecules by shaking the plate for 45 min at 550 RPM. The beads were then washed with another 150 μL of peptide exchange assay buffer #2 and resuspended in 150 μL of assay buffer before the fluorescent signals of each sample were recorded on a flow cytometer.

2.4. Peptide exchange quantitation by flow cytometry

The experiments were performed on the CytoFLEX LX (Beckman Coulter) flow cytometry instrument. The FSC and SSC voltages, gains and thresholds were adjusted so that the magnetic beads used for the capture assay were detected as a unique population separate from the background signals. The flow cytometer was then used to measure the Median Fluorescence Intensity (MFI) of the FITC signal that resulted from the exiting peptide antibody binding to the captured MHC tetramers on the magnetic beads.

2.5. Peptides

All peptides for these experiments synthesized at the 95% purity level were purchased from KareBay Biochem, Monmouth NJ. The peptides were diluted to 10 mM stocks in 100% DMSO and stored at −20 °C. Further peptide dilutions before each binding experiment were done with HPLC grade H2O.

2.6. In silico prediction of peptide binding affinities for MHC molecules

All of the theoretical binding affinities were derived from the Immune Epitope Database (IEDB) web resource funded by NIAID. This website catalogues experimental data on antibody and T cell epitopes resulting from numerous studies in the context of infectious disease, allergy, autoimmunity and transplantation. The accumulated data is then compiled and analyzed to allow the pre-
diction of peptide binding affinities for specific MHC molecules. The IEDB ANN and SMM-align methods were used respectively for MHC class I and II prediction [10,11].

| Key Resource Table |
|-------------------|
| REAGENT           | SOURCE          | PRODUCT NUMBER |
| QuickSwitch™ Quant HLA-A*02:01 Tetramer Kit-PE | MBL International Corporation | TB-7300-K1 |
| QuickSwitch™ Quant HLA-A*03:01 Tetramer Kit-PE | MBL International Corporation | TB-7306-K1 |
| QuickSwitch™ Quant HLA-A*11:01 Tetramer Kit-PE | MBL International Corporation | TB-7304-K1 |
| QuickSwitch™ Quant HLA-A*24:02 Tetramer Kit-PE | MBL International Corporation | TB-7302-K1 |
| QuickSwitch™ Quant H-2 Kb Tetramer Kit-PE | MBL International Corporation | TB-7400-K1 |
| QuickSwitch™ Quant HLA-DRB1*01:01 Tetramer Kit-PE | MBL International Corporation | TB-7500-K1 |
| QuickSwitch™ Quant HLA-DRB1*04:01 Tetramer Kit-PE | MBL International Corporation | TB-7502-K1 |
| QuickSwitch™ Quant HLA-DRB1*15:01 Tetramer Kit-PE | MBL International Corporation | TB-7506-K1 |

2.6.1. Preparation of MHC class II tetramers with peptide exchanged monomers

25 μL of MHC Class II QuickSwitch monomers were mixed with 2 μL of emulsifier, 3 μL of 10 mM COVID-19 peptides as well as the negative control, the CLIP peptide. Each peptide exchange monomer (30 μL) was mixed with 10 μL streptavidin-PE. The tetramers were then mixed with 10 μL Neutralizer.

2.6.2. PBMC stimulation and CD4 + T cell staining with MHC class II tetramers

PBMCs from healthy donors expressing HLA-DRB1*01:01, HLA-DRB1*04:01 and HLA-DRB1*15:01 were cultured for 2 weeks at 1 × 10^6 cells per mL in Aim V medium (Thermofisher) with supplemented IL-2 at 50 U/mL and 5% human AB serum and stimulated with SARS-CoV-2 peptides each at 10 μg/mL.

3. Results

The ability of a number of SARS-CoV-2 virus derived peptides as potential binders to MHC molecules were tested. Using the SMMA-lign and ANN methods of the IEDB web resource the IC50 theoretical binding affinities of peptides derived from the viral proteome to each of the tested MHC molecules were determined [10,11]. A few specific SARS-CoV-2 peptides with a high theoretical binding affinity for the MHC molecules in question were then loaded into MHC molecules using the parameters of the QuickSwitch kits.

In silico prediction, while an indispensable tool for modern studies on T cell stimulation, does not always predict the right peptide that would be able to bind to the MHC molecule’s peptide binding groove, not to mention, stimulate the T cells needed to fight infection or disease, especially when it comes to MHC Class II molecules [12]. The following results, obtained with recombinant MHC molecules (MBL International), can be used in the future to determine the nature of the T cell immune responses to SARS-CoV-2 without questioning what viral peptide sequences can be presented by which MHC molecules. In addition, it will simplify custom MHC tetramer generation with peptides that have shown to be good binders. While the QuickSwitch platform can only model the actual antigen presentation processes occurring inside of a cell, a recent white paper that describes mouse immune response to a recombinant SARS-CoV-2 Spike-Fc protein has shown that most of H-2 Kb QuickSwitch tetramers exchanged with SARS-CoV2 peptides reacted with CD8 T cells from these mice [13].

Using the HLA-A*02:01, HLA-A*03:01, HLA-A*24:02, HLA-A*11:01 and H-2 Kb QuickSwitch™ Quant Tetramer Kits, we were able to identify a number of peptides that bound to each MHC haplotype (Table 1). The identified SARS-CoV-2 peptides effectively displaced the exiting peptide which was selected for each individual MHC haplotype to easily dissociate from the MHC molecule to allow for the binding of even moderately strong peptides. When more than 75% of the exiting peptide is exchanged with a target peptide, the resulting tetramer can be used for CD8 + T cell staining. An exchange rate of higher than 90% corresponds to binding affinities in the low nanomolar range, while exchange rates lower than 65% are indicative of weak peptide-MHC interactions (data not shown). In contrast to MHC class II binding peptides there is very little binding promiscuity among class I alleles with one notable exception: HLA-A3 and HLA-A11. These 2 alleles are tightly related and all the tested peptides that were highly exchangeable on HLA-A3 also happened to be good HLA-A11 binders.

To address similar studies in mouse models, we attempted to assess the utility of the platform in a mouse MHC haplotype. A set of predicted strong binding peptides were tested for their ability to load in H-2 Kb MHC tetramers. Mouse H-2 Kb specific SARS-CoV-2 peptides can be used for T cell immunomonitoring in mouse models of COVID-19 studies [12]. Interestingly, two of the identified H-2 Kb peptides were also determined to be good HLA-A*02:01 binders (Table 2).

The exact exchange ratios of the tested HLA-A*02:01 Tetramer-PE molecules with each SARS-CoV-2 peptide can be visualized in Fig. 1. All HLA-A*02:01 exchange ratios following a 4-hour incubation can be compared to the exchange ratio of the HLA-A*02:01 reference peptide (Fig. 1, last bar in the graph). This peptide has been specifically selected and engineered to have one of the strongest interactions with the peptide binding groove of the HLA-A*02:01 molecule. The reference peptide is able to exchange a significant amount of the exiting peptide even when less than 1 μM of it is used for the exchange reaction.

As an illustration of the effectiveness of in silico prediction algorithms, we compared the theoretical binding affinity of the studied peptides determined by IEDB and the peptide exchange ratio resulting from the QuickSwitch assay. While most of the peptides determined to have low nanomolar Kd values readily exchange with the exiting peptide of the HLA-A*02:01 molecule, even among the peptides which we have tried there are a few exceptions. Some peptides with low theoretical Kd values show a low binding ability to the QuickSwitch HLA-A*02:01 assay and some peptides that should theoretically be bad binders display a high binding capacity for HLA-A*02:01 (Fig. 2). It is those outliers, which may hold the greatest insight into how the immune system may be skewed to resolve an infection or pathology and our QuickSwitch platform provides an effective mechanism to identify them.

We tested 19 SARS-CoV-2 peptides selected with the IEDB web resource for their ability to bind to recombinant HLA-DRB1*01:01, HLA-DRB1*04:01 and HLA-DRB1*15:01 molecules. All of the selected peptides were 15 amino acids in length with various bind-
Summary of SARS-CoV-2 peptide binding to mouse H-2 Kb MHC molecules.

| FLAHIQWMV | SARS-CoV-2 ORF1ab (3122–3130) | * |
| FLINENYL | SARS-CoV-2 ORF1ab (3183–3191) | * |
| LLLDDYPE | SARS-CoV-2 ORF1ab (6749–6758) | * |
| LLYDAYFL | SARS-CoV-2 ORF3a protein (139–147) | * |
| SMSWHELV | SARS-CoV-2 ORF1ab (3732–3740) | * |
| TLLMNLYTV | SARS-CoV-2 ORF1ab (3710–3718) | * |
| YLDAYNMMI | SARS-CoV-2 ORF1ab (6419–6427) | * |
| YLNITLAV | SARS-CoV-2 ORF1ab (6851–6859) | * |
| YLYALVYFL | SARS-CoV-2 ORF1ab (107–115) | * |
| YNYLYRLF | SARS-CoV-2 Chain A, spike glycoprotein (449–456) | + |
| AAYYGVSL | SARS-CoV-2 ORF1ab polyprotein (5573–5580) | + |
| SIIAYTMSL | SARS-CoV-2 Chain A, spike glycoprotein (691–699) | + |
| FYGGWYLM | SARS-CoV-2 ORF1ab (4986–4994) | * |
| VNFNFNGL | SARS-CoV-2 Chain A, spike glycoprotein (539–546) | + |
| MAYRENGL | SARS-CoV-2 Chain A, spike glycoprotein (902–909) | + |
| NINTREVIL | SARS-CoV-2 Chain A, spike glycoprotein (233–241) | + |
| VYVFSELL | SARS-CoV-2 Chain A, spike glycoprotein (511–518) | + |
| SIVRFENI | SARS-CoV-2 Chain A, spike glycoprotein (325–332) | + |
| GNYNLYRL | SARS-CoV-2 ORF1ab polyprotein (447–455) | * |
| VYVFVTVT | SARS-CoV-2 Chain A, spike glycoprotein (1060–1068) | + |
| SIANYMMS | SARS-CoV-2 ORF1ab polyprotein (691–699) | + |
| VTCLVLKGM | SARS-CoV-2 ORF1ab polyprotein (5385–5393) | + |
| ITGVYTL | SARS-CoV-2 ORF1ab polyprotein (5573–5580) | + |
| AAYYGVSL | SARS-CoV-2 Chain A, spike glycoprotein (263–270) | + |
| VNYLYLRF | SARS-CoV-2 Chain A, spike glycoprotein (449–456) | + |

4. Discussion

There are concerns that some vaccine researchers focus only on humoral responses to establish the potency and efficacy of their CoV-2 vaccines. This concern stems from the fact that the durability and potency of SARS-CoV-2 vaccines is indeed partially dictated...
by elicited T cell immune responses. Not examining the CoV-2 T cell immunomonitoring may result in vaccines that induce short lasting humoral responses in the absence of proper T cell memory responses [19–24]. Other than healthy hosts, it is also important to analyze CoV-2-specific T cell responses in certain vaccinated sub-populations such as the elderly, and hosts who bear underlying conditions that are expected to impact the immune system such as diabetes. To better understand the breath of T cell immune responses, three essential steps need to be interrogated, i) it is necessary to identify protein pieces (peptides) that can be processed in antigen processing pathways, ii) to identify those that are able to interact with the groove of MHC molecules, and iii) to validate those peptides with human PBMCs to ensure that there are T cell clonotypes recognizing these peptides in the context of self MHC. This short communication addresses the second item which is MHC occupancy testing of a selected sets of peptides that are reported in the past few months based on either in silico prediction models and/or after validation in PBMCs of hosts. These peptides should be validated in a system other than the one they are predicted in [25]. The QuickSwitch platform for the generation of
custom tetramers has proven itself to be a robust tool for the identification of peptides that can form a stable complex with both Class I and Class II MHC molecules as well as for T cell staining. Unlike in-silico systems, the platform used for this study involves the quantitation of real peptide binding to recombinant MHC molecules which can then be used to make tetramers and stain T cells. This allows the users to focus on finding populations of T cells that react to a specific viral peptide without worrying about whether this peptide can be presented by the MHC molecules or if the MHC tetramer that they are using is defective. In addition, the strong-binding peptides that we discovered in this short study can be used for multiple applications and assays. It is expected that these findings can be used by other labs to decipher what viral peptides have the most relevance to fighting the Covid-19 pandemic.

**Declaration of Competing Interest**

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

**References**

[1] Abraham J. Passive antibody therapy in COVID-19. Nat Rev Immunol 2020;20(7):401–3. https://doi.org/10.1038/s41577-020-0365-7.

[2] Weiskopf D, Schmitz KS, Raadsen MP, Grifoni A, Okba NMA, Endeman H, et al. Phenotype of SARS-CoV-2-specific T-cells in COVID-19 patients with acute respiratory distress syndrome. MedRxiv 2020:2020.04.11.20062349. https://doi.org/10.1101/2020.04.11.20062349.

[3] Braun J, Loyal L, Frensch M, Wendisch D, Georg P, Kurth F, et al. Presence of SARS-CoV-2 reactive T cells in COVID-19 patients and healthy donors. MedRxiv 2020:2020.04.17.20061440. https://doi.org/10.1101/2020.04.17.20061440.
[4] Purcell AW, McCluskey J, Rossjohn J. More than one reason to rethink the use of peptides in vaccine design. Nat Rev Drug Discov 2007;6(5):404–14. https://doi.org/10.1038/nrd2224.

[5] Blankenstein T, Coulie PG, Gilboa E, Jaffe EM. The determinants of tumour immunogenicity. Nat Rev Cancer 2012;12(4):307–13. https://doi.org/10.1038/nrc3246.

[6] Croft NP, Smith SA, Pickering J, Sidney J, Peters B, Faridi P, et al. Most viral peptides displayed by class I MHC on infected cells are immunogenic. Proc Natl Acad Sci U S A 2019;116(8):3112–7. https://doi.org/10.1073/pnas.1815239116.

[7] Sette A, Vitello A, Reherman B, Fowler P, Nayersina R, Kast WM, et al. The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes. J Immunol 1994;153:5586–92.

[8] Kosalog˘lu-Yalçın Z, Lanka M, Frentzen A, Logandha Ramamoorthy Premlal A, Sidney J, Vaughan K, et al. Predicting T cell recognition of MHC class I restricted neoepitopes. Oncoimmunology 2018;7(11):e1492508. https://doi.org/10.1080/2162402X.2018.1492508.

[9] Delcommenne MC, Hrytsenko O, Tram C, Weir G, Stanford MM. The QuickSwitch Quant HLA-A*02:01 Tetramer Kit can be used for determining the biological activity of a cancer vaccine. J Immunol 2017;198:79.27 LP-79.27.

[10] Nielsen M, Lundegaard C, Lund O. Prediction of MHC class II binding affinity using SMM-align, a novel stabilization matrix alignment method. BMC Bioinf 2007;8:238. https://doi.org/10.1186/1471-2105-8-238.

[11] Nielsen M, Lundegaard C, Worning P, Lauemøller SL, Lamberth K, Buus S, et al. Reliable prediction of T-cell epitopes using neural networks with novel sequence representations. Protein Sci 2003;12(5):1007–17. https://doi.org/10.1110/ps.0239403.

[12] Hoo WPY, Siak PY, In LLA. In Silico-Guided Sequence Modification of Epitopes in Cancer Vaccine Development. Methods Mol Biol 2020;2131:213–28. https://doi.org/10.1007/978-1-4939-9450-2_6.

[13] Herrmann A, Maruyama J, Yue C, Lahtz C, Zhou H, Kerwin L, et al. Determinants of the peptide-induced conformational change in the human class II major histocompatibility complex protein HLA-DR1. J Biol Chem 2000;275(3):2165–73. https://doi.org/10.1074/jbc.275.3.2165.

[14] Uddbäck I, Cartwright EC, Scheller AS, Wein AN, Hayward SL, Lobby J, et al. Long-term maintenance of lung resident memory T cells is mediated by persistent antigen. Mucosal Immunol 2021;14(1):92–9. https://doi.org/10.1038/s41385-020-0309-3.

[15] Hartman IZ, Kim AeRyon, Cotter RJ, Walter K, Dalai SK, Boronina T, et al. A reductionist cell-free major histocompatibility complex class II antigen processing system identifies immunodominant epitopes. Nat Med 2010;16(11):1333–40. https://doi.org/10.1038/nm.2346.

[16] Kim AeRyon, Hartman IZ, Poore B, Boronina T, Cole RN, Song N, et al. Divergent paths for the selection of immunodominant epitopes from distinct antigenic sources. Nat Commun 2014;5(1). https://doi.org/10.1038/ncomms6349.

[17] Wilson E, Hirneise G, Singharoy A, Anderson KS. Total predicted MHC-I epitope load is inversely associated with mortality from SARS-CoV-2. MedRxiv 2020:2020.05.08.20095430. https://doi.org/10.1101/2020.05.08.20095430.

[18] Sidhom J-W, Baras AS. Analysis of SARS-CoV-2 specific T-cell receptors in ImmuneCode reveals cross-reactivity to immunodominant Influenza M1 epitope. BioRxiv 2020;2020.06.20.160499. https://doi.org/10.1101/2020.06.20.160499.

[19] Smith CC, Chai S, Washington AR, Lee SJ, Landoni E, Field K, et al. Machine-Learning Prediction of Tumor Antigen Immunogenicity in the Selection of Therapeutic Epitopes. Cancer Immunol Res 2019;7(10):1591–604. https://doi.org/10.1158/2326-6066.CIR-19-0155.